Stryker (SYK) Earnings Date & Reports
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices... Show more
SYK is expected to report earnings to rise 34.23% to $3.49 per share on July 30
Stryker Corporation (SYK) Q1 2026 Earnings Recap: Cyber Disruption Drives Earnings Miss
Key Takeaways
- Stryker reported Q1 2026 net sales of $6.0 billion, a 2.6% increase year-over-year on a reported basis and 2.4% organically, missing consensus estimates of approximately $6.3 billion.
- Adjusted diluted EPS came in at $2.60, down 8.5% from the prior year and well below analyst expectations of around $2.98 to $3.00.
- GAAP EPS rose 14.2% to $1.93, supported by operational resilience amid challenges.
- MedSurg and Neurotechnology segment sales grew 0.9% organically to $3.2 billion; Orthopaedics up 4.1% organically to $2.8 billion.
- Full-year 2026 guidance reaffirmed: organic sales growth of 8.0% to 9.5% and adjusted EPS of $14.90 to $15.10.
- Shares fell about 2.3% in after-hours trading following the release.
Earnings Context and Why It Matters
Stryker Corporation, a leading medical technology company specializing in orthopaedics, MedSurg, and neurotechnology products, released its first quarter fiscal 2026 results on April 30, 2026. This report is critical for investors as it provides insights into procedure demand recovery post-cyber incident, segment performance amid supply chain pressures, and the company's ability to sustain growth in a competitive medtech landscape. With prior quarters showing robust double-digit organic growth, Q1 results test Stryker's operational resilience and set the tone for achieving full-year targets in an environment of moderating elective procedures and macroeconomic headwinds.
Stryker's Q1 2026 net sales reached $6.0 billion, reflecting 2.6% reported growth, 2.4% organic growth (driven by 2.1% higher unit volume and 0.3% price increases), and 1.0% constant currency growth compared to the prior year. This fell short of Wall Street consensus around $6.3 billion. Adjusted operating income margin contracted 180 basis points to 21.1%.
Adjusted diluted earnings per share (EPS) totaled $2.60, a decline of 8.5% year-over-year, significantly underperforming expectations of $2.98 to $3.00. GAAP EPS increased 14.2% to $1.93. Segment-wise, MedSurg and Neurotechnology delivered $3.2 billion in sales (up 0.9% organically), while Orthopaedics reported $2.8 billion (up 4.1% organically).
Management attributed the shortfalls primarily to a cyber incident impacting manufacturing and sales, from which the company has recovered. Full-year guidance remains unchanged, signaling confidence in underlying momentum.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Following the Q1 release, Stryker shares dropped approximately 2.3% to $321.43 in after-hours trading, reflecting investor disappointment with the EPS and revenue misses despite the reaffirmed guidance. Sentiment appears cautious, with focus on the cyber incident's lingering effects, though management’s commitment to full-year targets tempered some concerns. Analysts continue to view Stryker favorably long-term given its market leadership.
Forward Outlook and Key Factors to Monitor
Stryker reaffirmed its full-year 2026 guidance, projecting 8.0% to 9.5% organic net sales growth and adjusted EPS of $14.90 to $15.10, incorporating modestly positive pricing and favorable foreign exchange impacts. Investors should watch execution on this trajectory post-cyber recovery.
Key areas include sustained demand in orthopaedics, particularly joint replacements, and MedSurg product lines like endoscopy. Margin expansion will depend on cost controls and supply chain stability. Upcoming catalysts encompass new product launches and potential M&A (mergers and acquisitions) activity, as Stryker maintains a strong balance sheet.
Broader industry dynamics, such as elective procedure volumes and reimbursement trends, remain pivotal. Track Q2 results for evidence of accelerating growth toward full-year goals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices